Shares of biopharmaceutical company Soleno Therapeutics, Inc. (SLNO) were in the spotlight on Monday after the company ...

Soleno Therapeutics (SLNO) announced the U.S. commercial availability of VYKAT XR extended-release tablets, the company’s treatment for ...

Amendment reflects improved covenants and aligns with Company's strategic focus on cannabis VANCOUVER, British Columbia, April 14, 2025 (GLOBE NEWSWIRE) -- Village Farms International, Inc. ("Village ...

First prescriptions delivered to individuals with PWSREDWOOD CITY, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- Soleno ...

The FDA has approved Vykat XR (diazoxide choline) for the treatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome.

Karin Clarke, IPWSO Board Trustee and Chairperson for the PWS Support Group in South Africa, added: “Thank you to Soleno Therapeutics for their dedication and commitment to developing VYKAT™ XR (DCCR) ...

Thank you to Soleno Therapeutics for their dedication and commitment to developing VYKAT™ XR (DCCR) and getting approval from the US FDA. Thanks also to The Foundation for Prader-Willi Research ...

The FDA’s approval of VYKAT XR for the treatment of hyperphagia in patients with PWS came with a clean label and reasonable monitoring requirements. This outcome represents a best-case scenario for ...